News for Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma. Learn why BDTX stock is a Buy.

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. ( BDTX), a clinical-stage oncology company developing MasterKey therapies

Net Income: Achieved a net income of $56.5 million for Q1 2025, a significant turnaround from a net loss of $18.2 million in Q1 2024.Cash Position: Ended Q1 20

Black Diamond Therapeutics (BDTX) reports a stellar first quarter with substantial revenue growth. Noteworthy cash and investments increase to $152.4 mi

Black Diamond Therapeutics (BDTX) reported a robust financial standing at the close of the first quarter, boasting approximately $152.4 million in cash, cash eq

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 tr

Black Diamond Therapeutics (BDTX) Q1 2025 highlights: GAAP EPS of $0.98 & $70M revenue beat estimates. Strong $152.4M cash reserves.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Black Diamond Therapeutics Inc (BDTX). The firm reduced its

Black Diamond Therapeutics' partnership with Servier presents a major buying opportunity. BDTX is trading below its net cash of $2.30 per share. See more here.

On March 19, 2025, BB Biotech AG made a significant move by reducing its position in Black Diamond Therapeutics Inc (NASDAQ: BDTX). The firm sold 5,784,292 shar

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercia

**media[570609,570610]**

**media[544704]**

BB Biotech AG, a prominent investment firm, recently executed a significant transaction by acquiring an additional 3,140,000 shares of Black Diamond Therapeutic

Shares of Sage Therapeutics, Inc. SAGE rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen’s nonbinding $7.22/share a...

**media[453635]**

Preliminary results for BDTX-1535 in NSCLC patients are expected in early 2025. Read more about Black Diamond Therapeutics and the outlook for BDTX stock.

Market Overview Today's trading session exhibited a negative bias throughout the day. Major indices faced slight declines initially, which intensified in the af